Disease Burden and Access to Biologic Therapy in Patients with Severe Asthma, 2017–2022: An Analysis of the International Severe Asthma Registry
Tham Le,David Price,Clement Erhard,Bill Cook,Anna Quinton,Rohit Katial,George Christoff,Luis Perez-de-Llano,Alan Altraja,Celine Bergeron,Arnaud Bourdin,Mariko Koh,Lauri Lehtimäki,Bassam Mahboub,Nikolaos Papadopoulos,Paul Pfeffer,Chin Kook Rhee,Victoria Carter,Neil Martin,Trung Tran
DOI: https://doi.org/10.2147/jaa.s468068
2024-10-25
Journal of Asthma and Allergy
Abstract:Tham T Le, 1 David B Price, 2– 4 Clement Erhard, 5 Bill Cook, 6 Anna Quinton, 7 Rohit Katial, 8 George C Christoff, 9 Luis Perez-de-Llano, 10 Alan Altraja, 11, 12 Celine Bergeron, 13 Arnaud Bourdin, 14 Mariko Siyue Koh, 15, 16 Lauri Lehtimäki, 17, 18 Bassam Mahboub, 19 Nikolaos G Papadopoulos, 20, 21 Paul Pfeffer, 22, 23 Chin Kook Rhee, 24 Victoria Carter, 2, 3 Neil Martin, 25, 26 Trung N Tran 1 On behalf of the EVEREST Study Working Group 1 BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA; 2 Observational and Pragmatic Research Institute, Singapore; 3 Optimum Patient Care Global, Cambridge, UK; 4 Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK; 5 BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK; 6 Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA; 7 BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK; 8 Global Medical Respiratory, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA; 9 Faculty of Public Health, Medical University Sofia, Sofia, Bulgaria; 10 Department of Respiratory Medicine, University Hospital Lucus Augusti, Lugo, Spain; 11 Department of Pulmonology, University of Tartu, Tartu, Estonia; 12 Lung Clinic, Tartu University Hospital, Tartu, Estonia; 13 Centre for Lung Health, Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada; 14 PhyMedExp, University of Montpellier, CNRS, INSERM, University Hospital of Montpellier, Montpellier, France; 15 Respiratory and Critical Care Medicine, Singapore General Hospital, Singapore; 16 Duke-NUS Medical School, Singapore; 17 Allergy Centre, Tampere University Hospital, Tampere, Finland; 18 Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; 19 Rashid Hospital, Dubai Health Authority, Dubai, United Arab Emirates; 20 Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK; 21 Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece; 22 Department of Respiratory Medicine, Barts Health NHS Trust, London, UK; 23 Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK; 24 Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Seoul St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Seoul, South Korea; 25 Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK; 26 University of Leicester, Leicester, UK Correspondence: Trung N Tran, BioPharmaceuticals Medical, Respiratory and Immunology, AstraZeneca, Gaithersburg, MD, USA, Email Introduction: Patients with severe asthma may be prescribed biologic therapies to improve disease control. The EVEREST study aimed to characterize the global disease burden of patients with severe asthma without access to biologics and those who have access but do not receive biologics, as well as the remaining unmet need despite use of these therapies. Methods: This was a historical cohort study of patients with severe asthma (aged ≥ 18 years) in the International Severe Asthma Registry receiving Global Initiative for Asthma (GINA) 2018 step 5 treatment, or with uncontrolled disease at GINA step 4. Prospective data on patient clinical characteristics, healthcare resource utilization, and medication use over a 12-month period between December 2017 and May 2022 were assessed for the following five groups: biologics accessible (omalizumab, mepolizumab, reslizumab, benralizumab, or dupilumab); biologics inaccessible; biologics accessible but not received; biologics accessible and received; and biologic recipients whose asthma remained suboptimally controlled. Results: Overall, 9587 patients from 21 countries were included. Among patients in the biologics accessible (n=5073), biologics inaccessible (n=3041), and biologics accessible but not received (n=382) groups, 41.4%, 18.7%, and 49.6% experienced at least two exacerbations, 11.5%, 10.5%, and 6.2% required at least one hospitalization, 47.9%, 54.6%, and 71.2% had uncontrolled asthma, and 23.9%, 8.6%, and 11.0% received long-term oral corticosteroids (LTOCS), respectively. Following biologic therapy, among patients who received biologics overall (n=2666) and among tho -Abstract Truncated-
immunology,allergy,respiratory system